Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06870994Not ApplicableNot Yet Recruiting

Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma

Role: lead

NCT06894407Not ApplicableNot Yet Recruiting

Intratumoral Targeted Hyperthermia Therapy (THT) for Stage 3C/3D/4M1 Cutaneous Metastatic Melanoma

Role: lead

NCT04877002Not ApplicableTerminated

Performance Study of SONA Saliva C-19 Rapid Test

Role: lead

NCT05256589Not ApplicableCompleted

Clinical Evaluation of the SONA Saliva C-19 Rapid Self-Test for the Detection of COVID-19

Role: lead

All 4 trials loaded